RU2015154022A - OPHTHALMIC COMPOSITION FOR ZWITTERION SOFT CONTACT LENSES - Google Patents

OPHTHALMIC COMPOSITION FOR ZWITTERION SOFT CONTACT LENSES Download PDF

Info

Publication number
RU2015154022A
RU2015154022A RU2015154022A RU2015154022A RU2015154022A RU 2015154022 A RU2015154022 A RU 2015154022A RU 2015154022 A RU2015154022 A RU 2015154022A RU 2015154022 A RU2015154022 A RU 2015154022A RU 2015154022 A RU2015154022 A RU 2015154022A
Authority
RU
Russia
Prior art keywords
contact lenses
soft contact
ophthalmic composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2015154022A
Other languages
Russian (ru)
Other versions
RU2015154022A3 (en
RU2669558C2 (en
Inventor
Рицуко НАКАМУРА
Original Assignee
Сэндзю Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сэндзю Фармасьютикал Ко., Лтд. filed Critical Сэндзю Фармасьютикал Ко., Лтд.
Publication of RU2015154022A publication Critical patent/RU2015154022A/en
Publication of RU2015154022A3 publication Critical patent/RU2015154022A3/ru
Application granted granted Critical
Publication of RU2669558C2 publication Critical patent/RU2669558C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

1. Офтальмологическая композиция для цвиттерионных мягких контактных линз, включающая пранопрофен и/или его фармацевтически пригодную соль и хондроитинсульфат и/или его фармацевтически пригодную соль, и имеющая рН 5,5 или выше.1. Ophthalmic composition for zwitterionic soft contact lenses, including pranoprofen and / or its pharmaceutically acceptable salt and chondroitin sulfate and / or its pharmaceutically acceptable salt, and having a pH of 5.5 or higher. 2. Офтальмологическая композиция для цвиттерионных мягких контактных линз по п. 1, где хондроитинсульфат натрия и/или его фармацевтически пригодная соль является хондроитинсульфатом натрия.2. An ophthalmic composition for zwitterionic soft contact lenses according to claim 1, wherein the sodium chondroitin sulfate and / or its pharmaceutically acceptable salt is sodium chondroitin sulfate. 3. Офтальмологическая композиция для цвиттерионных мягких контактных линз по п. 1 или 2, содержащая 0,05-3 вес./об. % хондроитинсульфата и/или его фармацевтически пригодной соли.3. Ophthalmic composition for zwitterionic soft contact lenses according to claim 1 or 2, containing 0.05-3 weight./about. % chondroitin sulfate and / or its pharmaceutically acceptable salt. 4. Офтальмологическая композиция для цвиттерионных мягких контактных линз по по п. 1 или 2, где рН офтальмологической композиции составляет от 5,5 до 9.4. Ophthalmic composition for zwitterionic soft contact lenses according to claim 1 or 2, where the pH of the ophthalmic composition is from 5.5 to 9. 5. Офтальмологическая композиция для цвиттерионных мягких контактных линз по п. 1 или 2, содержащая 0,001-0,5 вес/об. % пранопрофена и/или его фармацевтически пригодной соли.5. Ophthalmic composition for zwitterionic soft contact lenses according to claim 1 or 2, containing 0.001-0.5 weight / vol. % pranoprofen and / or its pharmaceutically acceptable salt. 6. Офтальмологическая композиция для цвиттерионных мягких контактных линз по п. 1 или 2, которая является глазными каплями для цвиттерионных мягких контактных линз.6. An ophthalmic composition for zwitterionic soft contact lenses according to claim 1 or 2, which is an eye drop for zwitterionic soft contact lenses. 7. Способ подавления адсорбции пранопрофена и/или его фармацевтически пригодной соли на цвиттерионных мягких контактных линзах, включающий: добавление хондроитинсульфата и/или его фармацевтически пригодной соли к офтальмологической композиции для цвиттерионных мягких контактных линз, содержащей пранопрофен и/или его фармацевтически пригодную соль, и доведение рН офтальмологической композиции до 5,5 или выше.7. A method of suppressing the adsorption of pranoprofen and / or its pharmaceutically acceptable salt on zwitterionic soft contact lenses, comprising: adding chondroitin sulfate and / or its pharmaceutically acceptable salt to an ophthalmic composition for zwitterionic soft contact lenses containing pranoprofen and / or its pharmaceutically acceptable salt, and adjusting the pH of the ophthalmic composition to 5.5 or higher. 8. Применение жидкости, содержащей пранопрофен и/или его фармацевтически пригодную соль и хондроитинсульфат и/или его фармацевтически пригодную соль, и имеющей рН 5,5 или выше для получения офтальмологической композиции для цвиттерионных мягких контактных линз.8. The use of a liquid containing pranoprofen and / or its pharmaceutically acceptable salt and chondroitin sulfate and / or its pharmaceutically acceptable salt, and having a pH of 5.5 or higher to obtain an ophthalmic composition for zwitterionic soft contact lenses. 9. Способ подавления адсорбции пранопрофена и/или его фармацевтически пригодной соли на цвиттерионных мягких контактных линзах, включающий этап контакта с цвиттерионными мягкими контактными линзами жидкости, содержащей пранопрофен и/или его фармацевтически пригодную соль и хондроитинсульфат и/или его фармацевтически пригодную соль, и имеющей рН 5,5 или выше.9. A method of suppressing the adsorption of pranoprofen and / or its pharmaceutically acceptable salt on zwitterionic soft contact lenses, comprising the step of contacting the zwitterionic soft contact lenses of a liquid containing pranoprofen and / or its pharmaceutically acceptable salt and chondroitin sulfate and / or its pharmaceutically acceptable salt, and having pH 5.5 or higher.
RU2015154022A 2013-06-06 2014-05-27 Ophthalmic composition for zwitterionic soft contact lenses RU2669558C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013119946 2013-06-06
JP2013-119946 2013-06-06
PCT/JP2014/063961 WO2014196412A1 (en) 2013-06-06 2014-05-27 Ophthalmic composition for zwitterionic soft contact lens

Publications (3)

Publication Number Publication Date
RU2015154022A true RU2015154022A (en) 2017-07-14
RU2015154022A3 RU2015154022A3 (en) 2018-03-14
RU2669558C2 RU2669558C2 (en) 2018-10-12

Family

ID=52008062

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015154022A RU2669558C2 (en) 2013-06-06 2014-05-27 Ophthalmic composition for zwitterionic soft contact lenses

Country Status (6)

Country Link
JP (1) JP6366583B2 (en)
CN (1) CN105283183B (en)
HK (1) HK1217902A1 (en)
RU (1) RU2669558C2 (en)
TW (1) TWI626060B (en)
WO (1) WO2014196412A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346594B1 (en) * 1998-09-21 2002-02-12 Menicon Co., Ltd. Ocular lens material and process for producing same
JP4789479B2 (en) * 2004-02-23 2011-10-12 ロート製薬株式会社 Planoprofen-containing aqueous composition
JP2005247795A (en) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd Stable eye drops
JP4958401B2 (en) * 2004-12-28 2012-06-20 ロート製薬株式会社 Planoprofen-containing composition
JP4919666B2 (en) * 2005-01-26 2012-04-18 ロート製薬株式会社 Planoprofen-containing composition
JP5196130B2 (en) * 2005-12-27 2013-05-15 ライオン株式会社 Soft contact lens composition and adsorption suppression method
JP2008024701A (en) * 2006-06-21 2008-02-07 Rohto Pharmaceut Co Ltd Composition for soft contact lens comprising alginic acid or salt thereof
JP6009141B2 (en) * 2009-10-09 2016-10-19 ロート製薬株式会社 Aqueous composition
JP5846716B2 (en) * 2009-10-15 2016-01-20 ロート製薬株式会社 Ophthalmic composition for soft contact lenses
JP5909152B2 (en) * 2011-06-02 2016-04-26 ロート製薬株式会社 Aqueous composition containing tranilast

Also Published As

Publication number Publication date
RU2015154022A3 (en) 2018-03-14
CN105283183A (en) 2016-01-27
WO2014196412A1 (en) 2014-12-11
RU2669558C2 (en) 2018-10-12
HK1217902A1 (en) 2017-01-27
CN105283183B (en) 2018-08-24
TW201534351A (en) 2015-09-16
JPWO2014196412A1 (en) 2017-02-23
JP6366583B2 (en) 2018-08-01
TWI626060B (en) 2018-06-11

Similar Documents

Publication Publication Date Title
HRP20190627T1 (en) Ophthalmic formulation and method for ameliorating presbyopia
UA114597C2 (en) High concentration olopatadine ophthalmic composition
WO2016172712A3 (en) Ophthalmic composition
BR112014015349A8 (en) variable applanation patient interface
EA201490540A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
EA201491773A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE
EA201690212A1 (en) METHODS OF TREATMENT OR PREVENTION OF OPHTHALMIC PATHOLOGICAL CONDITIONS
BR112014030330A8 (en) OPHTHALMIC LENS, PAIR OF OPHTHALMIC LENSES AND VARIETY OF ADAPTED OPHTHALMIC LENSES TO BE WEARED BY A USER TAKING INTO CONSIDERATION ITS LATERALITY
EA201590520A1 (en) PHARMACEUTICAL COMPOSITION WITH COATING CONTAINING REGORAPHENIB
EA201290860A1 (en) TREATMENT OF RHEUMATOID ARTHRITIS BY COMBINATION OF LAKVINIMODA AND METHOREXAT
UA107753C2 (en) ACETYL-COA CARBOXYLASE REPLACED INHIBITORS
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
EA201390364A1 (en) MEANS FOR TREATING A DRINK
CL2011002606S1 (en) Trilage semi-ellipsoidal body epilator according to its smaller diameter, of sinusoid major faces and semi-cylindrical upper head of ends formed by spherical cap, with central rectangular recess and internal landscape cylinder; centered on the front, it has vertical rectangular relief, with semi-circular minor sides.
EA201300988A1 (en) SOFT PHARMACEUTICAL COMPOSITION ON WATER BASIS CONTAINING TAPENTADOL
JP2014211652A5 (en)
ES2538551R2 (en) Ophthalmic composition for the correction of presbyopia
RU2019139886A (en) THERAPEUTIC AGAINST DYSFUNCTION OF MEIBOMIUM GLANDS
EA201201239A1 (en) A composition comprising as active ingredients L-CARNITINE IN COMBINATION WITH hydroxykynurenine-O-BETA-DL-glucoside FOR PREVENTING AND / OR TREATING PATHOLOGIES eyes caused by ultraviolet radiation
RU2014140885A (en) PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND TRAMADOL FOR OPHTHALMIC USE
EA201400064A1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION THAT CONTAINS REGORAPHENIB
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
RU2016111957A (en) OPHTHALMIC COMPOSITION FOR ZWITTERION SOFT CONTACT LENSES
RU2016136333A (en) PHARMACOLOGICAL OPHTHALMOLOGICAL COMPOSITION USED IN CORRECTION OF PRESBIOPIA AND ITS INTRODUCTION
BR112018003717A2 (en) corrective lens apparatus and method

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200528